Chino, Calif. – September 13, 2026 -- Specialty Enzymes & Probiotics has published dual-track research showing its ingredient SlimSEBTM reduces post-meal blood sugar spikes by 16.90% in a controlled human clinical trial, providing formulators with clinically backed data for glucose-support supplements.
Clinical trial confirms 16.90% reduction in glucose AUC
In a double-blind, randomized, placebo-controlled crossover trial, subjects supplemented with SlimSEBTM showed a 16.90% reduction in Area Under the Curve (AUC), a standard measure of post-prandial glycemic response. The result demonstrates statistically significant improvement in blood sugar control following meals.
In vitro digestion model shows 34% cut in sugar release
A separate in vitro analysis using the INFOGEST digestion protocol, a globally recognized standard for simulating human digestion, found a 34% reduction in the release of simple sugars during digestion. Researchers attributed the effect to the conversion of sugars into fiber-like oligosaccharides with prebiotic potential, offering a secondary gut-health benefit alongside glycemic control.
Ingredient rebrand accompanies new data package
SlimSEBTM, formerly marketed as GlucoSEB PBTM, is positioned by the company as a next-generation glucose-support ingredient backed by both clinical and mechanistic evidence. "SlimSEBTM helps formulators deliver the precise glucose support consumers need,